GURU.Markets stock price, segment price, and overall market index valuation
The company's share price TRACON Pharmaceuticals
TRACON is a biotech company with a unique model that helps other companies develop oncology drugs. Its stock price reflects the success of these partnerships, diversifying risk.
Share prices of companies in the market segment - Dna
TRACON Pharmaceuticals is an oncology company developing targeted drugs and conducting clinical trials, including in partnership with other companies. We have classified it as a "DNA" company. The chart below shows how the market assesses the risks and prospects of biotech companies.
Broad Market Index - GURU.Markets
TRACON Pharmaceuticals is an oncology company developing targeted drugs for cancer treatment. As a participant in this sector, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it with the company's stock price to assess the outlook for this industry.
Change in the price of a company, segment, and market as a whole per day
TCON - Daily change in the company's share price TRACON Pharmaceuticals
The daily price change of TRACON Pharmaceuticals, Inc. reflects the extreme volatility inherent in biotech companies. This indicator measures the sensitivity to news about the clinical trials of its oncology drugs.
Daily change in the price of a set of shares in a market segment - Dna
TRACON Pharmaceuticals is a biopharmaceutical company developing targeted therapies for cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating TCON stock.
Daily change in the price of a broad market stock, index - GURU.Markets
TRACON is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization TRACON Pharmaceuticals
TRACON Pharmaceuticals' year-over-year performance tells the story of its unique business model. Its 12-month market capitalization depends on progress in clinical trials, where it leverages its expertise to develop drugs in partnership with other companies, allowing it to reduce the costs and risks associated with R&D.
Annual dynamics of market capitalization of the market segment - Dna
TRACON, as a biotech company with a unique development model, is committed to R&D efficiency. Its performance relative to the sector will demonstrate how its approach to clinical trial management enables it to achieve results at a lower cost, a key factor for small biotechs.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
TRACON, a biotech company with a lean development model, demonstrates with its dynamics whether it is possible to succeed in the pharmaceutical industry without huge expenditures. Its performance, compared to the market, is a test of the effectiveness of its strategy, where success depends on partnerships and the careful design of clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization TRACON Pharmaceuticals
TRACON is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its targeted drugs triggers an immediate and strong investor reaction, which is typical for biotech.
Monthly dynamics of market capitalization of the market segment - Dna
TRACON Pharmaceuticals is a biotech company developing targeted cancer drugs using a cost-effective model with active R&D outsourcing. The chart below illustrates the overall dynamics of the biotech sector, where TRACON strives to optimize drug development costs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
TRACON Pharmaceuticals is a biotech company developing cancer treatments. Its shares move not in sync with the market, but rather based on the results of clinical trials. The success or failure of a single trial can dramatically change the company's value.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization TRACON Pharmaceuticals
TRACON, a biotech company, shares weekly reflect its unique business model. Price movements reflect data from clinical trials, which the company conducts at minimal cost by collaborating with other companies, mitigating risk for investors.
Weekly dynamics of market capitalization of the market segment - Dna
TRACON Pharmaceuticals focuses on developing oncology drugs in partnership with other companies. This chart compares its weekly performance with the biotech sector and helps understand how its low-cost development model and partnership strategy are successful in this capital-intensive industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
TRACON Pharmaceuticals is a biotech company. Its success depends on the results of clinical trials. This chart will help you understand: does TRACON live in its own world of scientific news, or are the overall market conditions and risk appetite in the biotech sector actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
TCON - Market capitalization of the company TRACON Pharmaceuticals
TRACON's market capitalization tells the story of a biotech company with a unique business model aimed at reducing the costs of clinical trials. Its timeline tells the story of its drug development and whether its cost-effective model can succeed where others have failed.
TCON - Share of the company's market capitalization TRACON Pharmaceuticals within the market segment - Dna
TRACON Pharmaceuticals is an oncology company focused on effective drug development. Its small market share in its segment reflects its business model and the stage of its portfolio development. The chart below shows how the market perceives its ability to commercialize drugs.
Market capitalization of the market segment - Dna
TRACON Pharmaceuticals is a biotech company developing targeted therapies for cancer treatment. The chart below shows the overall market capitalization of the oncology sector. Its dynamics provide the backdrop against which TRACON is attempting to prove the efficacy of its drugs using a cost-effective clinical development model.
Market capitalization of all companies included in a broad market index - GURU.Markets
TRACON is a biotech company focused on efficiently developing oncology drugs. Its market capitalization reflects its unique business model and development pipeline. Its performance on the overall chart exemplifies how small companies navigate the highly competitive pharmaceutical landscape.
Book value capitalization of the company, segment and market as a whole
TCON - Book value capitalization of the company TRACON Pharmaceuticals
TRACON Pharma's foundation is its capital, which it uses to effectively conduct clinical trials of oncology drugs developed by other companies. This is a real, service-based, and scientific foundation that optimizes R&D. How has this unique "outsourced" biotech asset evolved? The chart below shows its dynamics.
TCON - Share of the company's book capitalization TRACON Pharmaceuticals within the market segment - Dna
TRACON Pharmaceuticals is a biopharmaceutical company focused on developing oncology drugs. The chart shows the share of its R&D assets, reflecting the physical foundation on which the company conducts its clinical trials.
Market segment balance sheet capitalization - Dna
TRACON, a biopharmaceutical company, has a lightweight model. It focuses on clinical trial management, outsourcing many functions. The biotech sector's BCap_Seg chart serves as a backdrop to its strategy—to be flexible and fast.
Book value of all companies included in the broad market index - GURU.Markets
TRACON's book value is derived from its pipeline of targeted cancer drug developments and its platform for efficient clinical trials. The company's assets are its intellectual property. The chart below shows how this biotech compares in terms of asset size.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - TRACON Pharmaceuticals
TRACON Pharmaceuticals is a biotechnology company focused on cost-effective drug development. Its balance sheet represents its pipeline. Its market capitalization reflects its business model, which is focused on reducing the costs of clinical trials.
Market to book capitalization ratio in a market segment - Dna
TRACON Pharmaceuticals has a unique business model: it efficiently conducts clinical trials of drugs developed by other companies in exchange for a share of their success. Its valuation on the chart reflects its project portfolio and its ability to cost-effectively manage research.
Market to book capitalization ratio for the market as a whole
TRACON Pharmaceuticals, an oncology company, focuses on drug development and commercialization. Its market valuation is a bet on the success of its clinical programs. This chart shows how high the biotech risk and potential premium is compared to the market average.
Debts of the company, segment and market as a whole
TCON - Company debts TRACON Pharmaceuticals
TRACON Pharmaceuticals, an oncology company using an efficient drug development model, is raising capital to conduct clinical trials. This chart shows how the company manages its resources to prove the efficacy of its drugs and find partners for their further commercialization, while minimizing its own costs.
Market segment debts - Dna
TRACON Pharmaceuticals is a biotech company that uses a lean model to develop oncology drugs, often through partnerships. This chart illustrates how the company manages its limited resources to advance its clinical programs while minimizing the need for external capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio TRACON Pharmaceuticals
TRACON Pharmaceuticals is a biotech company striving to develop oncology drugs more cost-effectively. This chart shows how it finances its clinical trials. It helps assess the extent to which its business model reduces its reliance on large amounts of debt compared to its competitors.
Market segment debt to market segment book capitalization - Dna
TRACON Pharmaceuticals is a biotech company focused on cost-effectively developing oncology drugs, often in partnership with other companies. The chart shows how aggressively the sector uses debt, providing context for assessing the success of TRACON's lean R&D model.
Debt to book value of all companies in the market
TRACON Pharmaceuticals, an oncology company that employs an efficient drug development model, strives to reduce R&D costs. This chart, showing the overall market leverage, provides context. It helps assess how successful its strategy is in maintaining a healthier capital structure compared to traditional biotech companies.
P/E of the company, segment and market as a whole
P/E - TRACON Pharmaceuticals
TRACON Pharmaceuticals is a biopharmaceutical company that utilizes a cost-effective drug development model, focusing on partnerships and efficient clinical trials. This chart shows how the market values its business model. This value is based on the success of its drugs in advancing through the clinical stages.
P/E of the market segment - Dna
This chart shows the average P/E valuation for biotech companies. For TRACON, with its China-focused drug development model, this provides important context. It helps understand the discount or premium investors are pricing in for its unique business strategy and the associated geopolitical risks and opportunities.
P/E of the market as a whole
TRACON Pharmaceuticals is a biotech company with a unique model that strives to efficiently develop drugs through outsourcing. Its valuation is dependent on the success of its clinical programs and the effectiveness of its business model. It is not tied to the overall economic trends shown in this chart.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company TRACON Pharmaceuticals
For TRACON Pharmaceuticals, Inc., a biopharmaceutical company developing targeted cancer therapies, this chart shows market expectations for its clinical programs. It reflects the projected success of its cost-effective development model.
%20P%2FE%20TRACON%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-TRACON-Pharmaceuticals&v=1772636526946 "Chart of the company's future (projected) P/E TRACON Pharmaceuticals")
Future (projected) P/E of the market segment - Dna
TRACON Pharmaceuticals is a biopharmaceutical company that utilizes a capital-efficient development model, focusing on targeted oncology and partnerships. This chart shows forecasts for the oncology sector. This helps assess how the market perceives TRACON's unique business model and the potential of its portfolio of drugs developed jointly with other companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772636527005 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted cancer therapies. The company uses a lean R&D model. This graph of overall risk appetite shows how willing investors are to support biotech companies with different approaches to drug development, including leaner ones.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772636527061 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit TRACON Pharmaceuticals
TRACON Pharmaceuticals is an oncology company focused on cost-effective drug development. It collaborates with other companies to conduct clinical trials. This chart illustrates how an alternative biotech business model attempts to reduce the enormous costs associated with drug development.
Profit of companies in the market segment - Dna
TRACON Pharmaceuticals is a biopharmaceutical company that utilizes a cost-effective drug development model, conducting clinical trials in partnership with the US National Cancer Institute. This graph, which charts profitability in the sector, demonstrates how companies are seeking ways to reduce development costs. Their strategy allows them to advance multiple oncology drugs with reduced financial risk.
Overall market profit
TRACON Pharmaceuticals is a biopharmaceutical company committed to developing and commercializing new cancer treatments at a lower cost. Its model is based on the efficient management of clinical trials. Success depends on the results of these trials. Overall economic stability, as demonstrated by the graph, is important for attracting capital for R&D.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company TRACON Pharmaceuticals
TRACON Pharmaceuticals is a biopharmaceutical company that utilizes a cost-effective drug development model, focusing on clinical trials in partnership with other companies. This chart reflects analyst expectations for the success of this model and the progress of its clinical programs.
%20profit%20of%20the%20company%20TRACON%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-TRACON-Pharmaceuticals&v=1772636527358 "Graph of future (projected) profit of the company TRACON Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Dna
TRACON Pharmaceuticals is a biopharmaceutical company that uses a capital-efficient development model to advance oncology drugs through clinical trials. Growth depends on the success of its candidates. This chart for the oncology sector shows the general expectations for innovative treatments and the growth potential for companies working in this field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772636527395 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
TRACON Pharmaceuticals is an oncology company committed to efficient drug development. Its business model relies on partnerships. The overall profit forecast shown in this chart influences the budgets of large pharma companies and their willingness to enter into collaboration agreements with small biotechs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772636527487 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - TRACON Pharmaceuticals
TRACON Pharmaceuticals is a biopharmaceutical company developing targeted drugs for cancer treatment. The chart shows how investors view its business model, which often involves partnerships and licensing. The valuation reflects the potential of its developments and its ability to effectively manage clinical trials.
P/S market segment - Dna
TRACON Pharmaceuticals focuses on the development and commercialization of targeted oncology drugs using a cost-effective development model. The company's valuation is based on the potential of its clinical programs. This chart, which displays the average valuation in the oncology field, provides context for understanding how the market views TRACON's development pipeline and business strategy.
P/S of the market as a whole
TRACON Pharmaceuticals is a biopharmaceutical company that utilizes a cost-effective drug development model, collaborating with other companies to conduct clinical trials. This chart, which reflects market revenue estimates, serves as a measure of investor expectations for TRACON's oncology pipeline.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company TRACON Pharmaceuticals
TRACON Pharmaceuticals is a biopharmaceutical company that utilizes an efficient drug development model by partnering with and conducting clinical trials for other companies. This chart reflects investor expectations regarding the success of its current clinical programs and its ability to identify new promising drugs for development.
%20P%2FS%20TRACON%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-TRACON-Pharmaceuticals&v=1772636527729 "The graph of the company's future (projected) P/S TRACON Pharmaceuticals")
Future (projected) P/S of the market segment - Dna
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted oncology therapies. The company utilizes an efficient product development model. This chart reflects average revenue expectations in the oncology sector. It allows investors to assess the market perception of TRACON's pipeline potential.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772636527757 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
TRACON Pharmaceuticals specializes in developing targeted oncology drugs using a cost-effective development model. This chart reflects overall investor sentiment. The company's strategy is aimed at maximizing the chances of success while minimizing costs, an important approach in the high-risk pharmaceutical industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772636527865 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales TRACON Pharmaceuticals
This chart shows the revenue of TRACON Pharmaceuticals, a biopharmaceutical company that uses a cost-effective model to develop and commercialize targeted oncology drugs. Its revenue is generated through partnerships, reflecting progress in clinical trials and the success of its business model.
Sales of companies in the market segment - Dna
TRACON Pharmaceuticals is an oncology company developing targeted drugs and conducting clinical trials. This chart reflects the dynamics of the biotech sector. The company's strategy for effective clinical trial management allows it to advance multiple programs, contributing to the overall search for new cancer treatments.
Overall market sales
TRACON Pharmaceuticals is a biopharmaceutical company developing targeted therapies for cancer treatment. Its growth depends on successful clinical trials and partnerships. The overall economic situation, shown in this chart, affects the availability of capital for funding cancer research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company TRACON Pharmaceuticals
TRACON Pharmaceuticals is an oncology company committed to efficient drug development through partnerships and thoughtful clinical trial design. Future revenue depends on the success of its pipeline. The schedule reflects expectations for the commercialization of its targeted therapies.
%20sales%20of%20the%20company%20TRACON%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-TRACON-Pharmaceuticals&v=1772636527993 "Schedule of future (projected) sales of the company TRACON Pharmaceuticals")
Future (projected) sales of companies in the market segment - Dna
TRACON Pharmaceuticals is a biopharmaceutical company that utilizes a cost-effective drug development model, collaborating with partners to conduct clinical trials. It focuses on oncology. This chart shows the forecast for the entire DNA therapeutics and oncology market, where efficient development cost management is key.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772636528010 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
TRACON Pharmaceuticals is a biopharmaceutical company using a capital-efficient development model to advance oncology drugs through clinical trials. This graph, reflecting overall market sentiment, impacts capital availability and partnership opportunities, which are at the core of their business model.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772636528040 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality TRACON Pharmaceuticals
TRACON Pharmaceuticals is a biotech company focused on cost-effective development of oncology drugs, often in partnership with other companies. Its financial model is designed to mitigate risk. This chart shows its net losses, which, however, may be lower than those of competitors thanks to outsourcing and joint development.
Market segment marginality - Dna
TRACON Pharmaceuticals is a biopharmaceutical company that utilizes a cost-effective drug development model by acquiring and developing promising oncology drugs. Profitability depends on the success of their clinical programs and strategic partnerships. This chart shows the operating results of their unique, cost-effective business model.
Market marginality as a whole
TRACON Pharmaceuticals is a biopharmaceutical company that uses a "productive development" model to effectively advance oncology drugs through clinical trials. They frequently collaborate with other companies. This overall profitability curve is irrelevant to them. Their success depends on competent clinical development management and positive data.
Employees in the company, segment and market as a whole
Number of employees in the company TRACON Pharmaceuticals
TRACON Pharmaceuticals uses a capital-efficient model, frequently collaborating with other companies to develop drugs. Its in-house staff is very small. This chart demonstrates its strategy of minimizing R&D costs through partnerships and outsourcing.
Share of the company's employees TRACON Pharmaceuticals within the market segment - Dna
TRACON Pharmaceuticals is a biopharmaceutical company that uses a lean model to develop oncology drugs. This chart reflects its strategy. It shows how a small core team can effectively manage clinical trials, often in partnership with other organizations, minimizing development costs.
Number of employees in the market segment - Dna
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted therapies for cancer treatment. This chart shows employment trends in the oncology sector. Fluctuations in the hiring of scientists and clinicians are directly related to clinical trial results and the company's strategic decisions regarding the development of its drug portfolio, often in partnership with other companies.
Number of employees in the market as a whole
TRACON Pharmaceuticals is a biotech company focused on developing oncology drugs. Its model incorporates partnerships to reduce costs. The overall economic environment, reflected in this chart, influences the availability of capital and the willingness of large pharmaceutical companies to enter into licensing deals for promising assets.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company TRACON Pharmaceuticals (TCON)
TRACON Pharmaceuticals is a biotech company that licenses and develops drug candidates in oncology. They use an "efficient R&D" model, outsourcing a significant portion of the work. The chart shows that with this model, the cost per full-time employee can be high, as a small team manages the development of several products.
%20of%20the%20company%20TRACON%20Pharmaceuticals%20(TCON)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-TRACON-Pharmaceuticals-TCON&v=1772636528526 "Chart of market capitalization per employee (in thousands of dollars) of the company TRACON Pharmaceuticals (TCON)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
TRACON Pharmaceuticals is a biopharmaceutical company that uses a cost-effective drug development model, often in partnership with other companies. This chart shows how the market values its drug portfolio and the effectiveness of its business model, which is focused on reducing clinical trial costs.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772636528542 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
TRACON Pharmaceuticals is a biopharmaceutical company developing targeted therapies for cancer treatment, focusing on sarcomas. The chart shows their valuation in the niche oncology field. It reflects how the market views their business model, which focuses on the efficient development of drugs for the treatment of rare cancers.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772636528566 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company TRACON Pharmaceuticals (TCON)
TRACON Pharmaceuticals is a clinical-stage biotech company specializing in the development of targeted oncology drugs. This is R&D. This chart shows the company's capital burn rate: the amount of capital the company spends on each scientist during expensive clinical trials.
%20Chart%20TRACON%20Pharmaceuticals%20(TCON)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-TRACON-Pharmaceuticals-TCON&v=1772636528611 "Company Profit Per Employee (in thousands of dollars) Chart TRACON Pharmaceuticals (TCON)")
Profit per employee (in thousands of dollars) in the market segment - Dna
TRACON Pharmaceuticals is a biotech company with a unique model. They strive to efficiently conduct clinical trials, leveraging their expertise and outsourcing to minimize costs. This metric (loss per employee) reflects their attempt to reduce capital burn on R&D.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772636528704 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
TRACON Pharma (TCON) is a biotech company that manages clinical trials (CRO model) for its oncology drugs (primarily through partnerships). It's an R&D business. This chart shows the capital burn rate: the operating loss per small team managing the trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772636528740 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee TRACON Pharmaceuticals (TCON)
TRACON Pharmaceuticals is a biopharmaceutical company developing targeted therapies for cancer treatment. This chart reflects the effectiveness of its partnership-based model. The growth in revenue per employee indicates successful advancement of drug candidates through clinical trials, leading to milestone payments from major pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-TRACON-Pharmaceuticals-TCON&v=1772636528840 "Sales chart per company employee TRACON Pharmaceuticals (TCON)")
Sales per employee in the market segment - Dna
TRACON Pharmaceuticals (TCON) is a biotech company specializing in oncology. They employ a cost-effective model, managing clinical trials (often through partnerships). This chart shows how productive their compact team is, measuring revenue (from partnerships) per employee.
Sales per employee for the market as a whole
TRACON Pharmaceuticals (TCON) is a biotech company that uses an asset-light model: it licenses and develops drugs, outsourcing many processes. The company has no commercial revenue. This chart illustrates the R&D situation: a small staff of managers and scientists coordinates clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company TRACON Pharmaceuticals (TCON)
TRACON Pharmaceuticals is a biotech company attempting to develop cancer drugs using a lean model. The bearish sentiment shown in this chart reflects investors' bets that its lead candidates will fail to receive FDA approval and that its business model is inefficient.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-TRACON-Pharmaceuticals-TCON&v=1772636529043 "Short Shares Chart for the Company TRACON Pharmaceuticals (TCON)")
Shares shorted by market segment - Dna
TRACON Pharmaceuticals (TCON) is a biotech company focused on developing targeted therapies for various cancers, including sarcomas. This chart shows the total volume of bearish bets against the entire oncology research sector. It's a sentiment indicator: if it's high, investors generally don't believe in rapid advances in this field or are concerned about trial failures.
Shares shorted by the overall market
TRACON Pharmaceuticals is a biotech company focused on oncology. This chart measures overall fear. When investors are pessimistic, they are unprepared for the binary risks of clinical trials. They sell off TCON shares, fearing the company will not have enough capital to complete R&D in a market panic and expensive financing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator TRACON Pharmaceuticals (TCON)
TRACON (TCON) is a biotech company that uses an outsourced R&D model to develop targeted oncology drugs to reduce costs. This oscillator measures price momentum. It helps identify when the stock is overheated (above 70) due to data expectations or oversold (below 30) due to news of funding delays or shortfalls.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-TRACON-Pharmaceuticals-TCON&v=1772636529254 "RSI 14 indicator chart for the company's stock TRACON Pharmaceuticals (TCON)")
RSI 14 Market Segment - Dna
TRACON Pharma is a biotech company and a cancer hunter. They focus on *antibodies* for the treatment of *solid* tumors (sarcoma). The RSI_14_Seg index for "Dna" (biotech/oncology) is driven by news. It helps us understand: is TCON's volatility due to their R&D, or is *the whole* biotech industry overheated?
RSI 14 for the overall market
TRACON Pharma (TCON) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TCON (TRACON Pharmaceuticals)
TRACON Pharmaceuticals is a biotech company seeking FDA approval for drugs already approved in Asia using a lower-cost R&D model. This chart shows the analysts' average 12-month forecast, reflecting their view on the risks and potential of this unique regulatory strategy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TCON-TRACON-Pharmaceuticals&v=1772636529386 "A chart showing analyst consensus forecasts for the expected stock price. TCON (TRACON Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price TCON (TRACON Pharmaceuticals)
TRACON (TCON) is a lean R&D biotech company that uses its asset-light model (outsourcing) to develop oncology drugs. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their view of the R&D portfolio and risks.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TCON-TRACON-Pharmaceuticals&v=1772636529416 "A chart showing the difference between the consensus forecast and the actual stock price. TCON (TRACON Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Dna
TRACON Pharma is a biotech company attempting to commercialize oncology drugs using an "efficient" R&D model (outsourcing trials). This chart shows general expectations for the DNA technology (and oncology) sector. It reflects whether experts believe in the success of the "R&D-lite" model.
Analysts' consensus forecast for the overall market share price
TRACON (TCON) is a boutique oncology biotech. It's a micro-cap company focused on developing drugs to treat rare cancers (sarcoma). This chart shows the overall risk appetite, reflecting how willing investors are to invest in the riskiest, most "lottery" tickets in the world of science.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index TRACON Pharmaceuticals
TRACON Pharmaceuticals uses a lean development model, outsourcing and managing oncology drug development to reduce costs. They focus on partnerships and molecules already approved in other countries. This chart is an integrated indicator that weighs the risks of clinical trials, the success of their partnership model, and the overall capital requirements for project completion.
AKIMA Market Segment Index - Dna
TRACON (TCON) is a DNA and oncology company. They not only develop their own drugs but also use their platform to quickly and affordably conduct clinical trials for others. This chart compares their hybrid index to the DNA technology sector average.
The AKIM Index for the overall market
TRACON Pharmaceuticals, a biopharmaceutical company developing envafolimab (an immunotherapy for sarcoma), has announced its liquidation. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop surrounding the company's demise.
